FDA guidance
Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry
FDA guidance · Final · issued Mar 1, 2023
Key facts
| Title | Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Mar 1, 2023 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2021-D-1047 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents